Lifetime Clinical Events Avoided And Resource Utilization With Apixaban Compared To Low-Molecular-Weight Heparin Followed By A Vitamin K Antagonist For The Treatment And Prevention Of Venous Thromboembolism
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.1358
https://www.valueinhealthjournal.com/article/S1098-3015(14)03288-4/fulltext
Title :
Lifetime Clinical Events Avoided And Resource Utilization With Apixaban Compared To Low-Molecular-Weight Heparin Followed By A Vitamin K Antagonist For The Treatment And Prevention Of Venous Thromboembolism
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)03288-4&doi=10.1016/j.jval.2014.08.1358
First page :
A475
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
844